Schuller E, Govaerts A
Eur Neurol. 1983;22(3):205-12. doi: 10.1159/000115560.
31 patients with multiple sclerosis were treated for an mean period of 4 years with high doses of human immunoglobulin. Overall, one third improved, one third showed no change and one third deteriorated. The effect of treatment was not related to any clinical or biological variable except perhaps the immunogenetic profile (HLA). The potential role of this symptomatic treatment is discussed.
31例多发性硬化症患者接受了高剂量人免疫球蛋白治疗,平均治疗期为4年。总体而言,三分之一的患者病情改善,三分之一无变化,三分之一病情恶化。除了免疫遗传特征(HLA)外,治疗效果与任何临床或生物学变量均无关联。本文讨论了这种对症治疗的潜在作用。